BOSTON, April 25, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, announced today ...
Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at ...
Pyxis Oncology, Inc. announced promising preclinical results for micvotabart pelidotin (MICVO), an antibody-drug conjugate targeting extradomain-B fibronectin (EDB+FN). The data, to be presented at ...
BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced positive ...
Pyxis Oncology , Inc. (NASDAQ: PYXS), a clinical-stage biotech company with a market capitalization of $68 million and strong liquidity position, announced Monday that revisions to patient enrollment ...
An updated edition of the July 21, 2025, article. The global cancer treatment market is entering a pivotal era, characterized by increasing cancer prevalence and rapid advancements in therapeutics. As ...
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX ...
46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results